NCT06348576招募中3 期
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 280
- 试验地点
- 1
- 主要终点
- Change rate of MSSBP
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of AD-209
详细描述
Condition or disease : hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Other inclusions applied
排除标准
- •Orthostatic hypotension with symptom
- •Other exclusions applied
研究组 & 干预措施
Test group
Experimental
AD-209+AD-2091 Placebo
干预措施: AD-209 (Drug)
Test group
Experimental
AD-209+AD-2091 Placebo
干预措施: AD-2091 Placebo (Drug)
Control group
Active Comparator
AD-2091+AD-209 Placebo
干预措施: AD-2091 (Drug)
Control group
Active Comparator
AD-2091+AD-209 Placebo
干预措施: AD-209 Placebo (Drug)
结局指标
主要结局
Change rate of MSSBP
时间窗: Baseline, Week 8
Change from baseline in mean sitting systolic blood pressure
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Efficacy and Safety of AD-209Hypertension, EssentialNCT05631990Addpharma Inc.221
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-223Hypertension,EssentialNCT06052748Addpharma Inc.502
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-224Hypertension,EssentialNCT06291207Addpharma Inc.254
已完成
2 期
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)Viral ConjunctivitisNCT01977443Adenovir Pharma AB47
招募中
3 期
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520